Analyst Ratings For NASDAQ:GEMP – Gemphire Therapeutics (NASDAQ:GEMP)
Today, Raymond James initiated coverage on NASDAQ:GEMP – Gemphire Therapeutics (NASDAQ:GEMP) with a Outperform with a price target of $22.00.
Some recent analyst ratings include
- 5/16/2018-Raymond James initiated coverage with a Outperform rating.
- 2/1/2018-HC Wainwright Reiterated Rating of Buy.
- 12/22/2017-Roth Capital Reiterated Rating of Buy.
- 10/27/2017-Piper Jaffray Reiterated Rating of Overweight ➝ Overweight.
- 10/23/2017-Canaccord Genuity Reiterated Rating of Buy.
- 9/16/2016-Royal Bank of Canada Reiterated Rating of Outperform.
Recent Insider Trading Activity For NASDAQ:GEMP – Gemphire Therapeutics (NASDAQ:GEMP)
NASDAQ:GEMP – Gemphire Therapeutics (NASDAQ:GEMP) has insider ownership of 22.70% and institutional ownership of 24.96%.
- On 2/8/2018 Steven R Ph.D. Gullans, Insider, bought 71,429 with an average share price of $7.00 per share and the total transaction amounting to $500,003.00.
- On 3/10/2017 Andy Sassine, Director, bought 21,119 with an average share price of $9.47 per share and the total transaction amounting to $199,996.93.
- On 8/10/2016 David Lowenschuss, Insider, bought 11,120 with an average share price of $10.00 per share and the total transaction amounting to $111,200.00.
- On 8/10/2016 Jeffrey S Mathiesen, CFO, bought 4,000 with an average share price of $10.00 per share and the total transaction amounting to $40,000.00.
- On 8/10/2016 Mina Sooch, CEO, bought 52,500 with an average share price of $10.00 per share and the total transaction amounting to $525,000.00.
- On 8/10/2016 Steven R Ph.D. Gullans, Director, bought 500,000 with an average share price of $10.00 per share and the total transaction amounting to $5,000,000.00.
Recent Trading Activity for NASDAQ:GEMP – Gemphire Therapeutics (NASDAQ:GEMP)
Shares of NASDAQ:GEMP – Gemphire Therapeutics closed the previous trading session at 6.31 up +0.76 13.65% with 6.159999847412109 shares trading hands.